On December 8, 2025 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, reported it will present new data demonstrating how comprehensive genomic profiling (CGP) can refine diagnosis and guide treatment decisions for patients with myeloid malignancies at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, which is being held Dec. 6–9, 2025, in Orlando, Florida.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster, "Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis," evaluated outcomes using the Neo Comprehensive Myeloid panel, a next-generation sequencing (NGS) assay that provides a complete view of genomic changes in myeloid cancers. By assessing mutations and fusions in a single test, this CGP panel detects important genomic variants that may otherwise be missed, and supports diagnosis, prognosis, and therapy selection for diseases such as acute myeloid leukemia (AML), myelodysplastic neoplasms (MDS), and myeloproliferative neoplasms (MPN).
Researchers analyzed data from 533 patients with myeloid disorders, integrating NeoGenomics’ molecular results with clinical data from national health information exchanges. The analysis found that in about one-third of patients tested, CGP identified pathogenic changes earlier in their disease, leading to diagnostic reclassification in several cases. It also revealed rare but clinically significant fusions—including PDGFRA, PDGFRB, FGFR1, and JAK2—that helped guide targeted treatment decisions.
"This study underscores our leadership in hematologic malignancy diagnostics and our long-standing commitment to improving cancer care in the community setting," said Warren Stone, President and Chief Operating Officer at NeoGenomics. "Patients living with complex blood cancers rely on timely and definitive answers, and their physicians deserve access to best-in-class molecular tools, regardless of practice location. Our next-generation myeloid CGP solution combines DNA and RNA sequencing in a single, comprehensive assay, providing actionable insights that smaller or DNA-only panels may miss. By expanding access to advanced diagnostics, we are enabling more personalized treatment decisions and working to improve the path to care for every patient, everywhere."
The study will be presented in session 908A, Outcomes Research: Myeloid Malignancies: Poster III, on December 8 from 6:00 to 8:00 p.m. ET. Conference attendees can also visit Booth #1971 in the ASH (Free ASH Whitepaper) 2025 Exhibit Hall to learn more about NeoGenomics’ hematology testing portfolio and ongoing research.
(Press release, NeoGenomics Laboratories, DEC 8, 2025, View Source [SID1234661294])